Lipid-lowering therapies for the secondary prevention of cardiovascular disease in primary care

An overview of updated guidance relating to the secondary prevention of cardiovascular disease can be applied in practice, considering the availability of newer medications.
Alirocumab (tradename Praluent) pen in use to administer subcutaneous injection

DR P. MARAZZI/SCIENCE PHOTO LIBRARY

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for over 30% of all global deaths​1​. In 2022, 39,000 people in England died prematurely of cardiovascular conditions, such as coronary heart disease and stroke in England​2​.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated
Peer reviewed article
This article has been peer reviewed by relevant subject experts prior to acceptance for publication. The reviewers declared no relevant affiliations or financial involvement with any organisation or entity with a financial involvement with any organisation or entity with a financial interest in or in financial conflict with the subject matter or materials discussed in this article.